Consolidated Sep 2026 quarter revenue up 36% versus Sep 2025; net loss narrows to Rs6.1 crore

Revenue growth above 20%Net loss reportedEBITDA margin expansionEmphasis of matterResults View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹221.50

prior close

₹223.53

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-4.1% vs market

Pharmaceuticals peers, median of 170sector+0.1%-3.9% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-2.0

15m

-1.7

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8+0.3-4.1+0.1-3.9

Next day

+0.4+2.4-2.0+1.1-0.7

-0.4+3.6-4.0+2.0-2.4

-1.1pendingpending+1.9-3.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue for the quarter ended September 30, 2026 rose 36.3% to Rs 434.2 crore from Rs 318.5 crore in Sep 2025; net loss narrowed to Rs 6.1 crore from Rs 34.9 crore. Margin before interest, tax, depreciation and amortisation rose from 2.3% to 10.3%. Consolidated half-year operating cash flow: positive Rs 166.9 crore. Auditor gave a clean review but flagged a pending environmental case; Rs 17.45 crore compensation order was stayed.

Likely market impact

Revenue and margins improved with positive cash flow, but continued losses and environmental and USFDA warning risks could weigh on the stock.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹434.2 Cr	₹318.5 Cr	+36.3%
Operating profit	−₹10.20 Cr	−₹48.90 Cr	loss narrowed
Profit after tax	−₹6.10 Cr	−₹34.90 Cr	loss narrowed
EBITDA margin	10.3%	2.3%	+8.1 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.